Sirtris Pharmaceuticals Co-Founder Presents First In-Vivo, Preclinical Data Showing SIRT1 Activation Can Suppress Tumor Formatio
February 20 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced that Sirtris co-founder David
Sinclair, PhD, Harvard Medical School Associate Professor of
Pathology, will present data showing that SIRT1
activation�can�suppress�tumor formation and growth in the intestine
and colon in a preclinical model of colon cancer. These are the
first in-vivo data showing that SIRT1�overexpression can�suppress
tumor formation and growth. These data are the work of Sirtris
Scientific Advisory Board co-chairs Sinclair and Leonard Guarente,
PhD, the Novartis Professor of Biology at the Massachusetts
Institute of Technology. The presentation will be held on Thursday,
February 28 at the J. David Gladstone Institutes, an independent,
non-profit biomedical research organization affiliated with the
University of California, San Francisco. About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that the Company believes
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, the potential therapeutic effects of SIRT1
activators for diseases of aging, such as Type 2 Diabetes and
cancer; the progress and results of pre-clinical studies of SIRT1
activators; and the potential of sirtuin modulators to receive
regulatory approval. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company's product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the Company to gain market acceptance of the Company's
product candidates, and those other risks factors that can be found
in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024